Colonic Pseudo-Obstruction (Ogilvie Syndrome)

Acute colonic dilation in the absence of a mechanical obstruction. First described by Sir William Heneage Ogilvie in 1948. Content below is from a textbook reference chapter (Sabiston Ch52 - Diverticular Disease, Obstruction & Pseudo-Obstruction), not primary literature.

Epidemiology and pathophysiology

Rare (~100/100,000 admissions). Hypothesized mechanism: dysregulation of colonic autonomic innervation, with relative sympathetic-over-parasympathetic excess, disrupted colonic reflex arcs, plus contributions from chronic disease and medications.

Classic setting: elderly, multiple comorbidities, following an acute illness (often hospitalization, medical or surgical).

Common associated conditions:

Presentation and diagnosis

Distension, pain, nausea/vomiting; obstipation common, though some patients have diarrhea from hypersecretion. Decreased/absent bowel sounds, or high-pitched tinkling sounds. Systemic toxicity or peritoneal signs are uncommon and should raise suspicion for ischemia/perforation.

• Plain film: cecum/right colon typically most dilated (can reach 10–12 cm); dilation and gas extending all the way to the rectum favors pseudo-obstruction over a mechanical obstruction (which usually shows a gas paucity distal to the obstruction point).
• Water-soluble contrast enema can reliably distinguish mechanical obstruction from pseudo-obstruction; CT is now typically used as the standard confirmatory test, also assessing for ischemia/impending perforation.
• Red flags for ischemia/perforation: abdominal tenderness, leukocytosis, fever, cecal diameter

  12 cm.

• Differential: mechanical obstruction, toxic megacolon (C. difficile or other causes).

Diagnostic criteria and incidence, per ASCRS Ch39 - Large Bowel Obstruction: there's no universally accepted formal definition, but in the appropriate clinical circumstances, imaging demonstrating a cecal diameter ≥~9cm or other colonic segments ≥~6cm may be classified as ACPO — a lower cecal threshold than this page's existing "10–12cm" framing above; flagged as a nuance in diagnostic-criteria stringency rather than a contradiction, since both figures come from the same broad literature on a condition without a single accepted cutoff. Estimated incidence ~100 per 100,000 hospital admissions annually in the US (matching this page's existing figure). ACPO is rarely a primary diagnosis and is most often identified in patients with some other active illness or state. Radiographic imaging typically shows a dilated, gas-filled colon with cecal dilation and a transition to more normal caliber near the splenic flexure — notably, this is roughly where midgut transitions to hindgut innervation, supporting the autonomic-dysregulation hypothesis for ACPO's pathophysiology. It's important to confirm there is no mechanical point of obstruction (intrinsic or extrinsic) before treating per the ACPO-specific algorithm below, since mechanical LBO is managed completely differently (see Large Bowel Obstruction).

Management (escalating by severity)

1. Supportive care — for cecal diameter <12 cm without ischemia/toxicity: NPO, correct electrolytes, stop contributing medications (opiates, anticholinergics, neuroleptics, antihistamines, clonidine), NG tube/rectal tube for decompression, ambulation, prone/knee-chest positioning to aid flatus passage. Avoid osmotic/stimulant laxatives (worsen dilation). Serial exams and abdominal films to monitor.
2. Neostigmine — acetylcholinesterase inhibitor, 2–2.5 mg IV bolus over 3–5 minutes in a monitored setting with atropine available. Success (flatus/bowel movement) 60–94%; recurrence in up to 31%. Contraindicated in mechanical obstruction and in ischemia/perforation; caution in asthma/COPD, bradycardia, recent ACS, renal failure. Common side effects: vomiting, cramping, salivation, bradycardia. Additional detail, per ASCRS Ch39 - Large Bowel Obstruction: neostigmine is not FDA-approved for this indication (an off-label use, based on placebo-controlled double-blind RCTs showing 85–94% efficacy — corroborating this page's existing 60–94% range at its upper end). Redosing in patients who don't respond adequately to a first dose is successful in 40–100% of cases. Risk factors associated with neostigmine failure: male gender, younger age, postoperative status, and electrolyte imbalances. After successful decompression, daily polyethylene glycol has been shown to decrease the risk of ACPO recurrence — a concrete, previously-unmentioned secondary-prevention measure. Contraindications also include intestinal or urinary tract obstruction and known hypersensitivity; glycopyrrolate co-administration may prevent bradycardia/hypersalivation side effects. Other pharmacologic agents used in refractory ACPO: oral pyridostigmine (a long-acting acetylcholinesterase inhibitor), methylnaltrexone (a peripherally-acting mu-opioid receptor antagonist), and prokinetics like metoclopramide and erythromycin.
3. Colonoscopic decompression — for neostigmine failure, contraindication, or unresponsiveness. Advance to the right colon with minimal insufflation, place a decompression tube. Initial success 61–95%, sustained success 70–90%; perforation rate 1–3%. Additional detail, per ASCRS Ch39 - Large Bowel Obstruction: despite some evidence that endoscopic decompression may be superior to pharmacotherapy, given the low cost/overall safety/efficacy of neostigmine, colonoscopy is generally reserved as a second-line treatment — consistent with this page's existing escalation ordering. Technique specifics: water immersion or minimal CO2 insufflation (rather than ambient air) is generally preferred; sedation typically relies on benzodiazepines and other non-narcotic agents, since narcotics can interfere with colonic motility; the goal of insertion is generally to reach the ascending colon (not necessarily the cecum), after which a long intestinal tube can be deployed to stent the colon for continued postprocedure decompression. Repeat colonoscopy may be required in as many as 40% of patients, especially if a long decompression tube isn't utilized. Symptoms often resolve within about 48 hours of successful colonoscopic decompression. Case reports describe endoscopic or CT-guided percutaneous cecostomy to vent/decompress ACPO patients, but this approach's utility isn't well documented.
4. Surgery — for patients who fail conservative measures or show toxicity/ischemia/perforation. Tube cecostomy or cecostomy if the colon is viable (high success rate); resection (usually with a diverting stoma) if ischemic or perforated. Additional detail, per ASCRS Ch39 - Large Bowel Obstruction: patients without a firm indication for surgery may undergo continued medical therapy with repeated pharmacotherapy/endoscopic decompression attempts before ultimately moving to a surgical intervention; timing/circumstances of proceeding to surgery are individualized, especially given operative mortality in the ACPO setting is itself variably reported as ~30% and as high as 60%. Patients with viable, non-perforated colon who require surgery most commonly undergo exploration to confirm the absence of compromised bowel, then are decompressed/vented via a colostomy — the role of colectomy itself in this scenario is questionable. Patients with an ischemic and/or perforated colon require resection of the diseased segment and are commonly left with an end stoma.

Escalation and mortality data: per a retrospective review of the National Inpatient Sample (ASCRS Ch39 - Large Bowel Obstruction, secondary/textbook-cited only), ACPO patients had progressively higher mortality with each escalation in therapy: 7.3% (medical therapy alone), 9.0% (colonoscopic decompression), and 12.3% (surgery) — consistent with sicker/more refractory patients requiring more invasive therapy, not necessarily with the therapy itself being more dangerous.

Ischemia/perforation occurs in an estimated 3–15% of cases and carries ~50% mortality when it does — the rationale for the escalating, time-sensitive protocol above. Related but distinct figures, per ASCRS Ch39 - Large Bowel Obstruction: the perforation rate associated with ACPO specifically (as opposed to the combined ischemia-or-perforation figure above) is reported as ranging from about 10% up to 30–40% in cases complicated by perforation — a wider and generally higher range than this page's existing combined figure. Flagged as a nuance (different endpoints — perforation alone vs. ischemia-or-perforation combined — drawn from different underlying literature) rather than a contradiction; not reconciled further here. The likelihood of ischemia/perforation increases as cecal diameter distends beyond ~10cm and as the duration of distension approaches or exceeds ~6 days, though larger cecal diameter, longer distension duration, and rate of distension are all independent contributing factors — meaningful perforation risk can occur even with less extreme dilation if the distension is acute.

Related pages

• Large Bowel Obstruction — the mechanical-obstruction counterpart this condition must be distinguished from before treating.
• Volvulus — a mechanical cause of colonic dilation that shares some radiographic overlap with ACPO and must be excluded via imaging/exam.

Open items / gaps

• No primary trial data in the wiki yet on neostigmine dosing/protocols or comparative effectiveness vs. colonoscopic decompression as first-line — ASCRS Ch39 - Large Bowel Obstruction cites the same class of placebo-controlled RCTs at the textbook/secondary level, but doesn't resolve this.
• ASCRS Clinical Practice Guidelines are referenced by the textbook as the fuller resource on this topic — not yet ingested directly.
• The 10–12cm vs. 9cm cecal-diameter diagnostic threshold, and the 3–15% (ischemia/perforation combined) vs. 10–40% (perforation alone) risk figures, are flagged above as nuances rather than resolved — worth checking against a primary source or the not-yet-ingested ASCRS guidelines.
• The National Inpatient Sample escalation-mortality study and the neostigmine-failure-risk-factor data (both per ASCRS Ch39 - Large Bowel Obstruction) are cited at the textbook/secondary level only.